PMC:7696151 / 86053-86239 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2538","span":{"begin":15,"end":23},"obj":"Species"},{"id":"2553","span":{"begin":153,"end":156},"obj":"Chemical"},{"id":"2554","span":{"begin":161,"end":171},"obj":"Chemical"}],"attributes":[{"id":"A2538","pred":"tao:has_database_id","subj":"2538","obj":"Tax:9606"},{"id":"A2553","pred":"tao:has_database_id","subj":"2553","obj":"MESH:D006886"},{"id":"A2554","pred":"tao:has_database_id","subj":"2554","obj":"MESH:D000069286"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Among eligible patients, 14% experienced a very good response, 14% minor responses, and 45% a period of stability in the disease when the association of HCQ and bortezomib were provided."}

{"project":"LitCovid-sentences","denotations":[{"id":"T547","span":{"begin":0,"end":186},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Among eligible patients, 14% experienced a very good response, 14% minor responses, and 45% a period of stability in the disease when the association of HCQ and bortezomib were provided."}